BC Extra | Nov 15, 2019
Financial News

Atomwise JV raises $14.5M series A to advance AI-discovered candidates

X-37 raised a $14.5 million series A to move forward AI platform-generated programs from Atomwise, which launched the JV last year with Velocity Pharmaceutical Development. DCVC Bio led Thursday’s round, with participation from Alpha Intelligence...
BioCentury | Mar 9, 2015
Finance

Column's creations

Including milestones, Bristol-Myers Squibb Co .'s takeout of Flexus Biosciences Inc. late last month is enough to return the capital of The Column Group's entire second fund. While it's the third quick exit for TCG,...
BC Innovations | Mar 6, 2014
Cover Story

Liver X receptor marks the spot

Multiple companies have shelved liver X receptor agonists for cardiovascular indications because of unfavorable effects on lipid levels. Now, a New York team and Rgenix Inc. have found a different role for the agonists in...
BioCentury | Oct 14, 2013
Strategy

Reviving Merck

As Merck & Co. Inc. 's new head of R&D, Roger Perlmutter plans to refocus and prune the pharma's pipeline of 31 Phase II and Phase III programs. But with half of its Phase III...
BioCentury | Jun 18, 2012
Finance

Leaders, not CEOs

Leaders, not CEOs Last week's $33 million series C round is expected to get cancer mAb company Igenica Inc. into the clinic, 5AM Ventures ' John Diekman told BioCentury. The company is running IND-enabling studies...
BioCentury | Aug 29, 2011
Emerging Company Profile

Novira: Capsid counterattack

Developing compounds against viral capsids is an attractive therapeutic strategy in theory, but has yet to work in practice because of the difficulty of inhibiting protein-protein interactions. Novira Therapeutics Inc. believes it has the right...
BC Extra | Jul 28, 2011
Financial News

Peloton races to $18M A round

Cancer company Peloton Therapeutics Inc. (Dallas, Texas) raised $18 million in a series A round led by The Column Group. Remeditex Ventures and individual investor Peter O'Donnell Jr. participated. Peloton in-licensed three early-stage small molecule...
BioCentury | Jul 4, 2011
Finance

Virtual Velocity

Virtual Velocity CMEA Capital is trying its hand at virtual development with newco Velocity Pharmaceutical Development LLC. Velocity plans to acquire early stage candidates, ensconce each in a company structure without an associated staff, develop...
BioCentury | Jul 12, 2010
Strategy

Biogen Idec's Agenda

Of all the first generation big cap biotechs, Biogen Idec Inc. has always been known as the stodgy one. Ironically, it has taken the intervention of activist investors - generally thought of as green eyeshade wearers...
BioCentury | Mar 22, 2010
Product Development

Playing turnabout

The dramatic effects of gastric banding surgery on diabetes published two years ago raised the question of whether the procedure could obviate the need for new diabetes drugs. But turnabout is fair play, as researchers...
Items per page:
1 - 10 of 276
BC Extra | Nov 15, 2019
Financial News

Atomwise JV raises $14.5M series A to advance AI-discovered candidates

X-37 raised a $14.5 million series A to move forward AI platform-generated programs from Atomwise, which launched the JV last year with Velocity Pharmaceutical Development. DCVC Bio led Thursday’s round, with participation from Alpha Intelligence...
BioCentury | Mar 9, 2015
Finance

Column's creations

Including milestones, Bristol-Myers Squibb Co .'s takeout of Flexus Biosciences Inc. late last month is enough to return the capital of The Column Group's entire second fund. While it's the third quick exit for TCG,...
BC Innovations | Mar 6, 2014
Cover Story

Liver X receptor marks the spot

Multiple companies have shelved liver X receptor agonists for cardiovascular indications because of unfavorable effects on lipid levels. Now, a New York team and Rgenix Inc. have found a different role for the agonists in...
BioCentury | Oct 14, 2013
Strategy

Reviving Merck

As Merck & Co. Inc. 's new head of R&D, Roger Perlmutter plans to refocus and prune the pharma's pipeline of 31 Phase II and Phase III programs. But with half of its Phase III...
BioCentury | Jun 18, 2012
Finance

Leaders, not CEOs

Leaders, not CEOs Last week's $33 million series C round is expected to get cancer mAb company Igenica Inc. into the clinic, 5AM Ventures ' John Diekman told BioCentury. The company is running IND-enabling studies...
BioCentury | Aug 29, 2011
Emerging Company Profile

Novira: Capsid counterattack

Developing compounds against viral capsids is an attractive therapeutic strategy in theory, but has yet to work in practice because of the difficulty of inhibiting protein-protein interactions. Novira Therapeutics Inc. believes it has the right...
BC Extra | Jul 28, 2011
Financial News

Peloton races to $18M A round

Cancer company Peloton Therapeutics Inc. (Dallas, Texas) raised $18 million in a series A round led by The Column Group. Remeditex Ventures and individual investor Peter O'Donnell Jr. participated. Peloton in-licensed three early-stage small molecule...
BioCentury | Jul 4, 2011
Finance

Virtual Velocity

Virtual Velocity CMEA Capital is trying its hand at virtual development with newco Velocity Pharmaceutical Development LLC. Velocity plans to acquire early stage candidates, ensconce each in a company structure without an associated staff, develop...
BioCentury | Jul 12, 2010
Strategy

Biogen Idec's Agenda

Of all the first generation big cap biotechs, Biogen Idec Inc. has always been known as the stodgy one. Ironically, it has taken the intervention of activist investors - generally thought of as green eyeshade wearers...
BioCentury | Mar 22, 2010
Product Development

Playing turnabout

The dramatic effects of gastric banding surgery on diabetes published two years ago raised the question of whether the procedure could obviate the need for new diabetes drugs. But turnabout is fair play, as researchers...
Items per page:
1 - 10 of 276